Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
Eupraxia Pharmaceuticals Inc. develops locally delivered, extended-release drug candidates using its proprietary Diffusphere technology, a polymer-based microsphere platform for targeted, controlled delivery. The company's news centers on clinical development of EP-104GI in eosinophilic esophagitis and EP-104IAR in knee osteoarthritis pain, including RESOLVE trial data, tissue-health and symptom measures, endoscopic and histologic scoring, and scientific conference presentations.
Recurring updates also cover financial results, clinical-supply and balance-sheet commentary, investor conference activity, and governance changes as Eupraxia advances its gastrointestinal and pain-focused development programs on Nasdaq and the TSX under EPRX.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) priced a public offering on Feb 19, 2026 to raise approximately US$55 million through 6,428,574 common shares at US$7.00 and pre-funded warrants for up to 1,428,571 shares at US$6.99999 each.
The Offering includes a 30-day underwriter option for an additional 1,178,571 common shares and is expected to close on Feb 20, 2026, subject to TSX and Nasdaq listing approvals. Proceeds are earmarked primarily to advance EP-104GI clinical programs, expand indications, R&D, business development and general corporate purposes.
Eupraxia Pharmaceuticals (NASDAQ:EPRX, TSX:EPRX) filed a preliminary prospectus supplement on Feb 18, 2026 for a proposed public offering of common shares (or pre-funded warrants) and may grant underwriters a 30-day option for up to an additional 15% of the offering.
The company intends to use net proceeds primarily to advance EP-104GI through preclinical work, Phase 2 and Phase 3 preparations, manufacturing, and commercial readiness, plus additional GI indications, R&D, business development, IP expansion and general corporate purposes. Closing is subject to customary conditions and required TSX and Nasdaq approvals.
Leviathan Metals (OTC:LVXFF) agreed to sell the Timor Gold Project (EL006278) in Victoria, Australia to Au Gold Corp in exchange for CAD$75,000 cash (CAD$10,000 on signing, CAD$65,000 on closing) and 5,000,000 Au Gold shares, representing 11.16% ownership of Au Gold as of Jan 16, 2026. Timor covers 116.45 km2 and hosts historic high‑grade workings including Leviathan Mine (documented production 181,000 tonnes for 67,511 oz at 11.4 g/t Au).
The MPSA includes contingent cash consideration of $3.00 per ounce for any JORC or NI 43‑101 resources disclosed, payable within 90 days of public disclosure. Closing is subject to TSX Venture Exchange approval. Separately, Leviathan entered a marketing services agreement for C$260,000 through Oct 31, 2026 with optional renewals.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive tissue health and symptom data from the ongoing Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis. At 12 weeks the highest-dose cohort (8mg/site, 20 sites, n=3) showed near-complete tissue normalization (EoEHSS Grade -0.57 [94%], Stage -0.63 [97%]). Patients in 4mg/site cohorts (n=9) maintained 12-week improvements at 36 weeks (Grade -0.22, Stage -0.24). Among patients with ≥60% esophagus treated, clinical remission was 58% at 12 weeks (n=19), 79% at 24 weeks (n=14), and 67% at 52 weeks (n=6). Safety: >200 patient-months in 31 patients with no SAEs and no oral candidiasis reported.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported additional 52-week follow-up data from the Phase 1b/2a RESOLVE trial of a single administration of EP-104GI for eosinophilic esophagitis (EoE) on Nov 13, 2025.
Cohort 6 (n=3) showed durable symptom response at 52 weeks: all three maintained clinical benefit and two remained in clinical remission; combined Cohorts 5 and 6 had 4 of 6 patients in remission at 52 weeks. Week-36 remission across Cohorts 5–7 was 67% (n=9). Across >200 patient-months there were no serious adverse events and no oral or GI candidiasis. Plasma fluticasone levels remained predictable and well below typical daily asthma inhaler levels.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q3 2025 results and a business update on Nov 4, 2025. Key items: 52-week durable symptom and tissue responses observed after a single EP-104GI treatment (two-thirds of Cohort 5, N=3 remained in remission at 1 year).
The company closed an $80.5 million public offering (14,636,363 shares at $5.50) and held $89.0 million cash as of Sept 30, 2025, with a stated runway into the first half of 2028. Topline Phase 2b RESOLVE data expected by Q3 2026.
Operational notes: net loss of $6.4M for Q3 2025; management is monitoring potential impacts from proposed U.S.-Canada tariffs on supply chain and costs.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive clinical data from Cohort 9 of the RESOLVE trial for EP-104GI in Eosinophilic Esophagitis, testing the highest dose of 8mg per injection. The results showed significant improvements in tissue health outcomes and eosinophil reduction, with patients experiencing rapid clinical remission and maintaining long-term benefits.
Based on these promising results, the company plans to expand the Phase 2b portion of RESOLVE from 60 to at least 120 patients. The trial will use 8mg per injection with 20 injections per administration. Additionally, Eupraxia intends to broaden EP-104GI's development program by initiating trials for additional GI indications in H1 2026, including potential applications in fibrostenotic Crohn's, benign esophageal strictures, and Barrett's esophagus prevention.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) has successfully closed its public offering of 14,636,363 common shares at US$5.50 per share, raising approximately US$80.5 million in gross proceeds. The offering included the full exercise of the underwriters' option to purchase additional shares.
The company plans to use the proceeds to advance its product pipeline, particularly the development of EP-104GI for eosinophilic esophagitis and its upcoming Phase 2b clinical readout. The funding is expected to extend the company's capital runway into the first quarter of 2028. Cantor and LifeSci Capital served as joint book-running managers, with Bloom Burton acting as co-manager for the offering.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced the pricing of its public offering of 12,727,273 common shares at US$5.50 per share, aiming to raise approximately US$70 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase up to an additional 1,909,090 shares under the same terms.
The offering, expected to close on September 24, 2025, is being managed by Cantor and LifeSci Capital as joint book-running managers, with Bloom Burton as co-manager. The proceeds will fund pipeline advancement, clinical trials, regulatory submissions, commercial preparation, and manufacturing scale-up activities. Additional uses include R&D for pipeline candidates, business development, and general corporate purposes.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced a proposed public offering of common shares. The company has filed a preliminary prospectus supplement to its base shelf prospectus for the offering, which includes a 30-day option for underwriters to purchase up to an additional 15% of shares.
The offering will be jointly managed by Cantor and LifeSci Capital as book-running managers, with Bloom Burton acting as co-manager. The proceeds will primarily fund the company's product pipeline development, including ongoing clinical trials, regulatory submissions, and commercial preparation. Additional uses include R&D for pipeline candidates, business development, and general corporate purposes.
The final terms and size of the offering will be determined at pricing, with completion subject to customary conditions including TSX and Nasdaq listing approvals.